HALO Sep 2024 50.000 put
OPR - OPR Delayed price. Currency in USD
Add to watchlist
At close: 11:37AM EDT
| Previous close | 2.1000 |
| Open | 2.0500 |
| Bid | 1.5500 |
| Ask | 2.3500 |
| Strike | 50.00 |
| Expiry date | 2024-09-20 |
| Day's range | 1.9000 - 2.0500 |
| Contract range | N/A |
| Volume | |
| Open interest | N/A |
Investor's Business DailyHow Small Biotech Halozyme, With A 41% Run, Is Getting Under Your Skin
Small biotech company Halozyme is behind some of the biggest names in medicine, including Johnson & Johnson's Darzalex and Roche's Tecentriq.
ZacksWhy This 1 Momentum Stock Could Be a Great Addition to Your Portfolio
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
PR NewswireHalozyme Announces Roche's OCREVUS® SC with ENHANZE® Receives European Commission Approval for Relapsing and Primary Progressive Multiple Sclerosis
Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced that Roche received European Commission (EC) marketing authorization of OCREVUS® (ocrelizumab) SC co-formulated with ENHANZE®, Halozyme's proprietary recombinant human hyaluronidase enzyme, rHuPH20, for the treatment of relapsing multiple sclerosis (RMS) and primary progressive multiple sclerosis (PPMS).
© 2024 Yahoo. All rights reserved.